FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.6_suppl.549
Abstract: 549 Background: Given that ICIs benefit a minority of mUC patients and are associated with significant costs, biomarkers are necessary to optimally utilize them in the clinic. Although FOXP3+ T-cells have been associated with an… read more here.
Keywords: muc treated; panel; urothelial carcinoma; response ... See more keywords
Impact of tumor burden on treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.764
Abstract: 764 Background: With the evolving treatment (tx) landscape in la/mUC, patient (pt) clinical characteristics are increasingly important when selecting systemic anticancer tx. This study describes pt characteristics, tx patterns, and clinical outcomes by tumor burden… read more here.
Keywords: avelumab 1lm; muc treated; treated avelumab; lymph node ... See more keywords
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.840
Abstract: 840 Background: ICIs offer modest response rates (~20%) in mUC and there remains a critical need for validated biomarkers to predict patient benefit. Hyperprogressive disease (HPD), characterized by rapid tumor progression following ICI initiation, is… read more here.
Keywords: immune genomic; muc treated; analysis; hpd ... See more keywords